EarlyDiagnostics

EarlyDiagnostics, Inc. is dedicated to providing accurate, affordable, and non-invasive liquid biopsy tests for early cancer detection and precision medicine. Its cost-effective proprietary technology for cell-free DNA methylation sequencing, combined with its robust AI algorithms, has achieved high performance in the early detection and localization of various cancers. The company’s scientific team has published numerous significant articles in prestigious journals, showcasing substantial contributions to the field’s science and leadership. EarlyDx plans to launch commercial products starting in 2024, offering early cancer detection and precision medicine testing to doctors and patients to improve patient health outcomes.